Abstract:Background The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains poor due to the difficulty of disease diagnosis and therapy. Immunotherapy has had robust performance against several malignancies, including PDAC. In this study, we aim to analyze the expression of CD8 and FoxP3 on T lymphocytes and TGF-β expression in tumor tissues, and then analyze the possible clinical significance of these finding in order to find a novel effective immunotherapy target in PDAC using a murine model. Methods A tissue microarray using patient PDAC samples was stained and analyzed for associations with clinicopathological characteristics. A preclinical murine model administrated with various immunotherapies were analyzed by growth inhibitor, flow cytometry, enzyme-linked immuno sorbent assay and immunohistochemistry. Results The infiltrating FoxP3 + regulatory T cells (Tregs) in tumor tissues were associated with survival, while CD8 + tumor infiltrating lymphocytes (TILs) were not. Considering the drawbacks of these measure alone, the number of CD8 + and FoxP3 + T cells were combined to create a new estimated value—integrated immune ratio (IIR), which showed excellent validity in survival risk stratification. IIR was further verified as an independent prognostic factor according to multivariate analysis as well as TGF-β expression. Association between TGF-β expression and infiltrating Tregs was also verified. Then, in our preclinical murine model, CD25 and TGF-β combination blockade had a higher tumor growth inhibitor value. This combination therapy significantly depleted periphery and intra-tumor FoxP3 + Tregs while increasing intra-tumor CD8 + TILs levels compared to controls or anti-TGF-β monotherapy ( p < 0.05). Anti-CD25 monotherapy alone also had the ability to deplete periphery and intra-tumor Tregs ( p < 0.05). The excretion of intra-tumor IL-10, TGF-β was notably lower but higher IFN-γ excretion in this combination immunotherapy. Such combination immunotherapy was further confirmed to synergize with anti-PD-1 monotherapy to improve tumor growth inhibition and cure rates. Conclusions The combination of CD25, TGF-β and PD-1 blockade plays a potentially effective role in inhibiting tumor formation and progression. Our results also provide a strong rational strategy for use of IIR in future immunotherapy clinical trials.

Limited Efficacy of Decreased Tumor-infiltrating Regulatory T Cells after Transforming Growth Factor-beta Blockade in Murine Pancreatic Ductal Adenocarcinoma

AB037. P008. Intratumoral Regulatory T Cells (tregs) Reduced by Neutralization TGF-β in Murine Pancreatic Ductal Adenocarcinoma Model Without Promising Functional Change

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Effect of blocking the transforming growth factor-beta signaling pathway on tumor-specific cytotoxic T lym-phocytes

CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer

Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness

Targeting TGFβR2‐mutant Tumors Exposes Vulnerabilities to Stromal TGFβ Blockade in Pancreatic Cancer

Blockade of Surface-Bound Tgf-Beta on Regulatory T Cells Abrogates Suppression of Effector T Cell Function in the Tumor Microenvironment

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.

Regulatory T cells in immune checkpoint blockade antitumor therapy

Transforming Growth Factor-Β2 Inhibition in Combination with Interleukin-2 Enhanced T-Cell Mediated Anti-Tumor Activities Via Attenuation of the Fibrotic Reaction in a Humanized Mouse Model of Pancreatic Ductal Adenocarcinoma

Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy

CCR8 Blockade Primes Anti-Tumor Immunity Through Intratumoral Regulatory T Cells Destabilization in Muscle-Invasive Bladder Cancer

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

Abstract A033: Blocking TNF-a producing macrophage activates antitumor immunity in pancreatic cancer via IL33

Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes

Combined Inhibition Of Tgf- Signaling And The Pd-L1 Immune Checkpoint Is Differentially Effective In Tumor Models

Low Intratumoral Regulatory T Cells and High Peritumoral CD8(+) T Cells Relate to Long-Term Survival in Patients with Pancreatic Ductal Adenocarcinoma after Pancreatectomy.

Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25-Foxp3+ T cells